cyclooxygenase inhibitors

Summary

Summary: Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Top Publications

  1. ncbi Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man
    Burkhard Hinz
    Institute of Toxicology and Pharmacology, University of Rostock, Schillingallee 70, D 18057 Rostock, Germany
    FASEB J 22:383-90. 2008
  2. ncbi Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events
    James M Scheiman
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
    Clin Ther 32:667-77. 2010
  3. ncbi Cyclooxygenases: structural, cellular, and molecular biology
    W L Smith
    Department of Biochemistry, Michigan State University, East Lansing, MI 48824, USA
    Annu Rev Biochem 69:145-82. 2000
  4. ncbi Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
    Enrico Flossmann
    Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford OX2 6HE, UK
    Lancet 369:1603-13. 2007
  5. pmc Prostaglandins and cancer
    D Wang
    The Vanderbilt Ingram Cancer Center, Room 698, Preston Research Building, 2300 Pierce Ave, Nashville, Tennessee 37232 6838, USA
    Gut 55:115-22. 2006
  6. ncbi Celecoxib for the prevention of colorectal adenomatous polyps
    Nadir Arber
    Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    N Engl J Med 355:885-95. 2006
  7. ncbi Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
    Francis K L Chan
    Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
    Lancet 376:173-9. 2010
  8. pmc Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2
    O Morteau
    Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Clin Invest 105:469-78. 2000
  9. ncbi Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer
    Sherven Sharma
    Department of Medicine, Lung Cancer Research Program, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1960, USA
    Cancer Res 65:5211-20. 2005
  10. pmc Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
    Tilo Grosser
    Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 116:4-15. 2006

Detail Information

Publications394 found, 100 shown here

  1. ncbi Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man
    Burkhard Hinz
    Institute of Toxicology and Pharmacology, University of Rostock, Schillingallee 70, D 18057 Rostock, Germany
    FASEB J 22:383-90. 2008
    ..In view of its substantial COX-2 inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for acetaminophen...
  2. ncbi Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events
    James M Scheiman
    Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
    Clin Ther 32:667-77. 2010
    ..However, NSAIDs have been associated with gastrointestinal (GI) toxicity. The cardiovascular (CV) toxicity associated with COX-2 inhibitors and some other NSAIDs further complicates the choice of therapy...
  3. ncbi Cyclooxygenases: structural, cellular, and molecular biology
    W L Smith
    Department of Biochemistry, Michigan State University, East Lansing, MI 48824, USA
    Annu Rev Biochem 69:145-82. 2000
    ..We further examine the evidence for independent signaling by PGHS-1 and PGHS-2, and the complex mechanisms for regulation of PGHS-2 gene expression...
  4. ncbi Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
    Enrico Flossmann
    Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford OX2 6HE, UK
    Lancet 369:1603-13. 2007
    ..However, the delay from the early development of adenoma to presentation with cancer is at least 10 years. We aimed to assess the longer-term effect of aspirin on the incidence of cancers...
  5. pmc Prostaglandins and cancer
    D Wang
    The Vanderbilt Ingram Cancer Center, Room 698, Preston Research Building, 2300 Pierce Ave, Nashville, Tennessee 37232 6838, USA
    Gut 55:115-22. 2006
    ..Recent efforts to identify the molecular mechanisms by which PGE(2) promotes tumour growth and metastasis may provide opportunities for the development of safer strategies for cancer prevention and treatment...
  6. ncbi Celecoxib for the prevention of colorectal adenomatous polyps
    Nadir Arber
    Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    N Engl J Med 355:885-95. 2006
    ..Overexpression of cyclooxygenase 2 (COX-2) has been associated with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention...
  7. ncbi Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
    Francis K L Chan
    Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
    Lancet 376:173-9. 2010
    ..We aimed to compare risk of gastrointestinal events associated with celecoxib versus diclofenac slow release plus omeprazole...
  8. pmc Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2
    O Morteau
    Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Clin Invest 105:469-78. 2000
    ....
  9. ncbi Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer
    Sherven Sharma
    Department of Medicine, Lung Cancer Research Program, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1960, USA
    Cancer Res 65:5211-20. 2005
    ..Transfer of Treg cells or administration of PGE2 to mice receiving COX-2 inhibitors reversed these effects. We conclude that inhibition of COX-2/PGE2 suppresses Treg cell activity and enhances antitumor responses...
  10. pmc Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
    Tilo Grosser
    Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 116:4-15. 2006
    ....
  11. ncbi Anti-inflammatory cembranoids from the soft corals Sinularia querciformis and Sinularia granosa
    Yi Lu
    Department of Marine Biotechnology and Resources, National Sun Yat Sen University, Kaohsiung 804, Taiwan, Republic of China
    J Nat Prod 71:1754-9. 2008
    ..However, compounds 3, 7, and 8 significantly inhibited the accumulation of the pro-inflammatory iNOS and COX-2 proteins in LPS-stimulated RAW264.7 macrophage cells...
  12. ncbi Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial
    Nancy R Cook
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    JAMA 294:47-55. 2005
    ..Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer...
  13. ncbi Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
    R A Gupta
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2279, USA
    Nat Rev Cancer 1:11-21. 2001
    ..Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment...
  14. pmc Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
    Paulo C Rodriguez
    Tumor Immunology Program, Stanley S Scott Cancer Center, New Orleans, LA, USA
    J Exp Med 202:931-9. 2005
    ..Furthermore, an addition of arginase I represents a clinical approach to enhance the therapeutic potential of cancer immunotherapies...
  15. pmc Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:3372-7. 2009
    ....
  16. pmc Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials
    Jan Magnus Bjordal
    Department of Public Health and Primary Health Care, University of Bergen, 5018 Bergen, Norway
    BMJ 329:1317. 2004
    ..To estimate the analgesic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase-2 inhibitors (coxibs), in patients with osteoarthritis of the knee...
  17. ncbi Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
    L Laine
    University of Southern California School of Medicine, Los Angeles, California 90033, USA
    Gastroenterology 120:594-606. 2001
    ..This review discusses the risks of clinical GI disease in NSAID users, the predictors of increased risk, and strategies for prevention of NSAID-associated GI disease...
  18. ncbi Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association
    Elliott M Antman
    Brigham and Women s Hospital, Harvard Medical School, USA
    Circulation 115:1634-42. 2007
  19. ncbi Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line
    X H Liu
    Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Exp Metastasis 17:687-94. 1999
    ....
  20. ncbi Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis
    Patrice Matchaba
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    Clin Ther 27:1196-214. 2005
    ..The cardiovascular (CV) safety of non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors has been the subject of considerable debate...
  21. ncbi Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2
    Patricia McGettigan
    Discipline of Clinical Pharmacology, School of Medicine and Public Health, The University of Newcastle, New South Wales, Australia
    JAMA 296:1633-44. 2006
    ..Regulatory agencies have provided variable advice regarding the cardiovascular risks with older nonselective NSAIDs...
  22. pmc Aspirin use and survival after diagnosis of colorectal cancer
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St, GRJ 722 Boston, MA 02114, USA
    JAMA 302:649-58. 2009
    ..Aspirin reduces risk of colorectal neoplasia in randomized trials and inhibits tumor growth and metastases in animal models. However, the influence of aspirin on survival after diagnosis of colorectal cancer is unknown...
  23. ncbi Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine
    Andrew R Haas
    Thoracic Oncology Research Laboratory, Philadelphia, Pennsylvania 19104 6160, USA
    Clin Cancer Res 12:214-22. 2006
    ..This study shows that the effectiveness of a cancer vaccine can be significantly improved by adding COX-2 inhibition...
  24. ncbi Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 106:566-75. 2006
    ..Based on potential additive or synergistic antitumor effects, interferon-alpha (IFNalpha) and celecoxib, an oral COX-2 inhibitor, were given to metastatic RCC patients in a Phase II trial...
  25. pmc Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
    Julia Hippisley-Cox
    Institution 13th floor, Tower Building, University Park, Nottingham NG2 7RD
    BMJ 330:1366. 2005
    ....
  26. ncbi Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1071-80. 2005
    ..Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern...
  27. pmc Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents
    Md Jashim Uddin
    AB Hancock, Jr Memorial Laboratory for Cancer Research, Department of Biochemistry, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 0146, USA
    Cancer Res 70:3618-27. 2010
    ....
  28. pmc COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells
    Mitsugu Fujita
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer Res 71:2664-74. 2011
    ..Taken together, our findings show that the COX-2 pathway promotes gliomagenesis by directly supporting systemic development of MDSCs and their accumulation in the TME, where they limit CTL infiltration...
  29. ncbi COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps
    Yuki Nakanishi
    Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto606 8507, Japan
    Carcinogenesis 32:1333-9. 2011
    ..Thus, our results suggest that COX-2 inhibition alters TAM phenotype in an IFN-γ-dependent manner and subsequently may reduce intestinal tumor progression...
  30. ncbi Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions
    Hedi Harizi
    Laboratoire d Immunologie, Unité Mixte de Recherche Centre National de la Recherche Scientifique, Universite Victor Segalen, Bordeaux 2, 33076 Bordeaux, France
    J Immunol 168:2255-63. 2002
    ..We conclude that COX-2-mediated PGE(2) up-regulates IL-10, which down-regulates IL-12 production and the APC function of BM-DC...
  31. ncbi Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2
    Ruxana T Sadikot
    Department of Veterans Affairs, Jesse Brown VA Hospital, Chicago, IL 60612, USA
    Eur J Immunol 37:1001-9. 2007
    ..Thus it is possible that inhibition of COX-2 or EP2 receptors could be an effective adjunctive treatment for severe or resistant P. aeruginosa pneumonia...
  32. pmc COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
    M Farooqui
    1Division of Hematology, Oncology and Transplantation, the Vascular Biology Center, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Cancer 97:1523-31. 2007
    ..In fact, the combination provided significantly better analgesia than with morphine or celecoxib alone. Clinical trials of this combination for analgesia in chronic and severe pain in cancer are warranted...
  33. ncbi Coxibs and cardiovascular disease
    Garret A Fitzgerald
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 351:1709-11. 2004
  34. pmc IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
    S Kotake
    The Institute of Rheumatology, Tokyo Women s Medical University, Tokyo 162 0054, Japan
    J Clin Invest 103:1345-52. 1999
    ....
  35. ncbi Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells
    Xiangguo Liu
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Natl Cancer Inst 96:1769-80. 2004
    ..We investigated the mechanism of celecoxib-induced apoptosis further...
  36. ncbi Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism
    Morten Søndergaard Jensen
    Perinatal Epidemiology Research Unit, Departments of Obstetrics and Pediatrics, Aarhus University Hospital, Skejby, Denmark
    Epidemiology 21:779-85. 2010
    ..We examined whether prenatal exposure to acetaminophen, ibuprofen, and acetylsalicylic acid was associated with increased occurrence of cryptorchidism...
  37. ncbi The contributions of cyclooxygenase-2 to tumor angiogenesis
    S Gately
    Department of Medicine, Northwestern University Medical School, Chicago, IL, USA
    Cancer Metastasis Rev 19:19-27. 2000
    ..These agents are safe and well tolerated and can be added to chemotherapy and radiation therapy where angiogenesis inhibitors appear to provide at least additive therapeutic benefit...
  38. pmc (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2
    Kelsey C Duggan
    Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Nat Chem Biol 7:803-9. 2011
    ....
  39. ncbi Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells
    Alexander V Timoshenko
    Department of Anatomy and Cell Biology, The University of Western Ontario, London, Ontario, Canada N6A 5C1
    Exp Cell Res 289:265-74. 2003
    ..Migration of poorly migratory MCF-7 cells remained unaffected with either PGE2 or EP4 antagonist. These findings are relevant for designing therapeutic strategies against breast cancer metastasis...
  40. ncbi Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line
    A Vivaldi
    Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
    Mol Cell Endocrinol 355:41-8. 2012
    ..A clinical trial exploring the in vivo activities of celecoxib in MTC patients who cannot benefit from available treatments would be desirable, taking into account the possible risks of cardiovascular effects of this drug...
  41. ncbi PGE(2) in the regulation of programmed erythrocyte death
    P A Lang
    Department of Physiology, University of Tubingen, Germany
    Cell Death Differ 12:415-28. 2005
    ..In FACS analysis, phospholipase-A(2) inhibitors quinacrine and palmitoyltrifluoromethyl-ketone, and cyclooxygenase inhibitors acetylsalicylic acid and diclophenac, blunted the increase of PS exposure following Cl(-) removal...
  42. ncbi The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis
    Ana Paula Ribeiro Paiotti
    Department of Pathology, Federal University of Sao Paulo, UNIFESP, SP, Brazil
    In Vivo 26:381-93. 2012
    ..In conclusion, the relative role of COX-2 selective inhibitors on human and experimental colitis remains to be explored. Thus, the use of COX-2 inhibitors in IBD should be considered with caution...
  43. ncbi Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF-κB and JNK activations in microglia cells
    Sang Keun Ha
    Graduate School of East West Medical Science, Kyung Hee University Global Campus, 1 Seocheon Dong, Giheung gu, Yongin, Gyeonggi Do 446 701, Republic of Korea
    Neurosci Lett 485:143-7. 2010
    ..These results suggest that chrysin may act as a potential therapeutic agent for various neurodegenerative diseases involving neuroinflammation...
  44. pmc In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines
    Z Adhim
    Division of Infectious Disease Control, Center for Infectious Disease, Kobe University Graduate School of Medicine, 7 5 1, Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    Br J Cancer 105:393-402. 2011
    ..In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells...
  45. pmc Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes
    C H Leo
    Health Innovation Research Institute, RMIT University, Bundoora, Victoria, Australia
    Br J Pharmacol 162:365-77. 2011
    ....
  46. ncbi NSAIDs and apoptosis
    N R Jana
    Cellular and Molecular Neuroscience Laboratory, National Brain Research Centre, Manesar, Gurgaon, India
    Cell Mol Life Sci 65:1295-301. 2008
    ..Both COX-2-dependent and COX-2-independent mechanisms are involved in NSAIDs-induced neoplastic growth. This article reviews the recent literature that has revealed various important mechanisms of NSAIDs-induced apoptosis...
  47. ncbi Analytical determination and pharmacokinetics of robenacoxib in the dog
    M Jung
    Novartis Animal Health Research Centre, St Aubin, Switzerland
    J Vet Pharmacol Ther 32:41-8. 2009
    ..In dogs, robenacoxib has good bioavailability after oral (84%) and subcutaneous (88%) administration...
  48. ncbi COX-2 as a target for cancer chemotherapy
    Nilanjan Ghosh
    Dr B C Roy College of Pharmacy and Allied Health Sciences, Durgapur, India
    Pharmacol Rep 62:233-44. 2010
    ..Large epidemiological trials studying users and non-users of aspirin have shown that cyclooxygenase inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) could be of benefit against the development and ..
  49. pmc Cyclooxygenases: structural and functional insights
    Carol A Rouzer
    A B Hancock Jr Memorial Laboratory for Cancer Research, Department of Biochemistry, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, TN 37232 0146, USA
    J Lipid Res 50:S29-34. 2009
    ..However, recent discoveries call this paradigm into question and reveal as yet underappreciated functions for both enzymes. This review focuses on some of these new insights...
  50. ncbi The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis
    C Alec Yen
    Department of Oral Medicine, Tufts University School of Dental Medicine, Boston, MA 02111, USA
    J Periodontol 79:104-13. 2008
    ..In this double-masked, placebo-controlled, randomized clinical trial, the efficacy of celecoxib (COX-2 inhibitor) was evaluated in conjunction with scaling and root planing (SRP) in subjects with chronic periodontitis (CP)...
  51. pmc Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma
    Erin M Burns
    Department of Pathology, The Ohio State University, Columbus, OH 43210, USA
    Carcinogenesis 34:370-7. 2013
    ..Our data suggest a new therapeutic use for currently available topical diclofenac as a preventative intervention for patients predisposed to cutaneous SCC development before lesions appear...
  52. ncbi Interventions for pain during fixed orthodontic appliance therapy. A systematic review
    Li Xiaoting
    State Key Laboratory of Oral Disease and Department of Orthodontics, West China School of Dentistry, Sichuan University, Chengdu, China
    Angle Orthod 80:925-32. 2010
    ..To compare the different methods of pain control intervention during fixed orthodontic appliance therapy...
  53. ncbi Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection caused by Streptococcus pyogenes
    Oliver Goldmann
    Infection Immunology Research Group, Department of Microbial Pathogenesis, Helmholtz Centre for Infection Research, Braunschweig, Germany
    J Immunol 185:2372-81. 2010
    ..pyogenes infected mice. Therefore, the results of this study open up new perspectives on potential molecular pathways that are prone to pharmacological manipulation during severe streptococcal infections...
  54. ncbi Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
    Matthew C Becker
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Am Heart J 157:606-12. 2009
    ..Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs). However, the relative cardiovascular safety of these therapies remains uncertain...
  55. ncbi Cyclooxygenase as a target for colorectal cancer chemoprevention
    Leticia Moreira
    Gastroenterology Department, Hospital Clinic, CIBERehd, IDIBAPS, University of Barcelona, Catalonia, Spain
    Curr Drug Targets 12:1888-94. 2011
    ....
  56. ncbi Gait analysis and pain response of two rodent models of osteoarthritis
    C E Ferland
    Faculty of Veterinary Medicine, Department of Veterinary Biomedicine, University of Montreal, Saint Hyacinthe, Canada
    Pharmacol Biochem Behav 97:603-10. 2011
    ..These results suggest that the MIA model may be more appropriate for the evaluation of short term pain studies and that celecoxib may modulate mechanical allodynia through central sensitization mechanisms...
  57. ncbi Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance
    Bing Liu
    Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jie Fang Road, Hangzhou, 310009, Zhejiang, People s Republic of China
    Cell Biol Int 34:21-5. 2010
    ..Therefore we can use the COX inhibitors to potentialize the effects of chemotherapeutic agents and reverse multidrug resistance to facilitate the patient who may benefit from addition of COX inhibitors to standard cytotoxic therapy...
  58. ncbi Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer
    Johnny Kao
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, USA
    Cancer 117:3173-81. 2011
    ..In the current phase 1 trial, the authors sought to determine the maximum tolerated dose (MTD) and efficacy of concurrent erlotinib and celecoxib as a radiosensitizing regimen...
  59. ncbi NSAIDs and the colon
    Angel Lanas
    Service of Digestive Diseases, University Hospital, CIBERehd IACS, University of Zaragoza, Zaragoza, Spain
    Curr Opin Gastroenterol 25:44-9. 2009
    ..To better understand the effects of NSAIDs on the colon...
  60. ncbi Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group
    Andrea Koch
    Allergy Centre Allergicentrum, University Hospital, Linkoping, Sweden
    Eur J Cancer 47:1546-55. 2011
    ..Experimental and clinical phase II trials have indicated that the addition of the COX-2 inhibitor celecoxib to palliative chemotherapy might increase survival time in patients with advanced NSCLC...
  61. ncbi Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery
    K Holte
    Department of Surgical Gastroenterology, Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    Br J Surg 96:650-4. 2009
    ..This study determined the rate of anastomotic leakage in a series of patients who had colonic surgery over a 9-year period with or without use of a cyclo-oxygenase inhibitor for postoperative analgesia...
  62. ncbi Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo
    Hans Axelsson
    Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, SE 413 45 Gothenburg, Sweden
    Int J Oncol 37:1143-52. 2010
    ..In conclusion, our results extend earlier studies on cell culture experiments and demonstrate that EGF-R and downstream KRas pathways communicate effects of increased prostaglandin activity in tumor tissue in vivo...
  63. ncbi Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study
    Yana Vinogradova
    Division of Primary Care, University of Nottingham, Nottingham, United Kingdom
    Gastroenterology 133:393-402. 2007
    ..Several studies suggest that statins prevent some cancers, with one study finding a 47% reduction in colorectal cancer risk after >or=5 years of regular use...
  64. pmc Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention
    Susan M Fischer
    Department of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, PO Box 389, Smithville, TX 78957, USA
    Cancer Prev Res (Phila) 4:1728-35. 2011
    ..A comprehensive understanding of the results of coxibs and other NSAIDs in animal studies may help inform and shape human trials of these commonly employed, relatively inexpensive, and highly effective compounds...
  65. ncbi Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo
    Kathleen M Leahy
    Pharmacia, Mail Zone AA4C, 700 Chesterfield Parkway, Chesterfield, Missouri 63017, USA
    Cancer Res 62:625-31. 2002
    ..2-3.0-fold) in response to celecoxib. Thus, the antitumor activity of celecoxib may be attributable, at least in part, to a direct effect on host stromal elements, such as the angiogenic vasculature...
  66. ncbi Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
    F Catella-Lawson
    University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
    J Pharmacol Exp Ther 289:735-41. 1999
    ..Our data suggest that acute sodium retention by nonsteroidal anti-inflammatory drugs in healthy elderly subjects is mediated by the inhibition of Cox-2, whereas depression of GFR is due to inhibition of Cox-1...
  67. ncbi Isolation of linoleic and alpha-linolenic acids as COX-1 and -2 inhibitors in rose hip
    A K Jäger
    Department of Medicinal Chemistry, The Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, DK 2100 Copenhagen, Denmark
    Phytother Res 22:982-4. 2008
    ..The COX-2/COX-1 ratio was 0.007 for linoleic acid and 0.2 for alpha-linolenic acid. Linoleic acid and alpha-linolenic acid contribute to the COX-1 and -2 inhibitory activity of rose hip...
  68. ncbi Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention
    Kemal Kismet
    4th General Surgery Department, Ankara Research and Training Hospital, Ulucanlar, Ankara, Turkey
    Cancer Detect Prev 28:127-42. 2004
    ..In this article, we reviewed COX-2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention...
  69. pmc Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step
    John W A Rossen
    Laboratory of Pediatrics, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    J Virol 78:9721-30. 2004
    ..MAPK and NF-kappaB pathways are involved in rotavirus infection but in a PGE2-independent manner. This report offers new perspectives in the search for therapeutic agents in treatment of severe rotavirus-mediated diarrhea in children...
  70. ncbi Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion
    Kasem Nithipatikom
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Clin Exp Metastasis 19:593-601. 2002
    ..Further, PGD2 may represent a weak inhibitor and counteracts the effect of PGE2 in the cell invasion...
  71. ncbi Prostacyclin protects against elevated blood pressure and cardiac fibrosis
    Helene Francois
    Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina 27705
    Cell Metab 2:201-7. 2005
    ..Our data suggest that adjuvant therapy that blocks unrestrained Tx actions might protect against end-organ damage without affecting blood pressure in patients taking COX-2 inhibitors...
  72. ncbi Molecular therapeutic targets in inflammation: cyclooxygenase and NF-kappaB
    Teresa Krakauer
    Department of Molecular Biology and Immunology, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Curr Drug Targets Inflamm Allergy 3:317-24. 2004
    ..Selective inhibitors of inflammation including cyclooxygenase inhibitors, antibodies against inflammatory cytokines, cytokine receptor antagonist, antibodies against adhesion ..
  73. pmc Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway
    Hongning Zhou
    Center for Radiological Research, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 102:14641-6. 2005
    ..These results provide evidence that the COX-2-related pathway, which is essential in mediating cellular inflammatory response, is the critical signaling link for the bystander phenomenon...
  74. pmc Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02120, USA
    Epidemiology 17:268-75. 2006
    ..Instrumental variable methods have been proposed as a potential approach to control confounding by indication in nonexperimental studies of treatment effects; however, good instruments are hard to find...
  75. ncbi Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental Trypanosoma cruzi infection
    M A Michelin
    Department of Biological Sciences, Immunology, Federal School of Medicine, Uberaba, MG, Brazil
    Exp Parasitol 111:71-9. 2005
    ..In conclusion, the results suggest that the prostaglandins produced mainly by COX-2 mediate the immunosuppression observed in the acute phase of T. cruzi infection...
  76. ncbi Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer
    Jurriaan B Tuynman
    Laboratory of Experimental Oncology, Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands
    Cancer Res 68:1213-20. 2008
    ....
  77. ncbi Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
    Pratima Sinha
    Department of Biological Sciences, University of Maryland Baltimore County, University of Maryland, Baltimore, Maryland 21250, USA
    Cancer Res 67:4507-13. 2007
    ....
  78. ncbi Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production
    K Sumitani
    Second Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, Tokyo, Japan
    J Oral Pathol Med 30:41-7. 2001
    ..These results suggest that specific inhibition of COX-2 inhibits proliferation of cancer cells expressing COX-2 mRNA via suppression of PGE2 production...
  79. ncbi The role of cyclooxygenases in inflammation, cancer, and development
    C S Williams
    Department of Medicine, The Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2279, USA
    Oncogene 18:7908-16. 1999
    ..The in vivo mechanism by which COX-2 affects tumor growth has not been determined. It is possible that both tumor and stromally derived COX-2 could influence tumor angiogenesis and/ or immune function...
  80. ncbi Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study
    Anne Marie Schjerning Olsen
    Department of Cardiology, Copenhagen University Hospital, Gentofte, Denmark
    Circulation 123:2226-35. 2011
    ..We therefore studied the duration of NSAID treatment and cardiovascular risk in a nationwide cohort of patients with prior myocardial infarction (MI)...
  81. ncbi Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases
    F A Attiga
    Department of Biology, George Washington University, Washington, DC 20037, USA
    Cancer Res 60:4629-37. 2000
    ....
  82. ncbi The comparative safety of analgesics in older adults with arthritis
    Daniel H Solomon
    Division of Pharmacoepidemiology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arch Intern Med 170:1968-76. 2010
    ..The safety of alternative analgesics is unclear. We examined the comparative safety of nonselective NSAIDs (nsNSAIDs), selective cyclooxygenase 2 inhibitors (coxibs), and opioids...
  83. ncbi Role of eicosanoids in prostate cancer progression
    D Nie
    Department of Radiation Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI 48202, USA
    Cancer Metastasis Rev 20:195-206. 2001
    ..The regulation of prostate cancer progression by eicosanoids, in either positive or negative ways, provides an exciting possibility for management of this disease...
  84. ncbi Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis
    R C Reddy
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Michigan Medical School, Ann Arbor, Michigan 48109-0360, USA
    Am J Physiol Lung Cell Mol Physiol 281:L537-43. 2001
    ..These results demonstrate that selective COX-2 inhibition confers early but not long-term benefits without affecting the expression of proinflammatory cytokines or the development of lung inflammation...
  85. ncbi Biology of Cox-2: an application in cancer therapeutics
    Zakir Khan
    INSERM U 955, Team No 10, Institut Mondor de Recherche Biomedicale, Universite Paris Est, 94010 Creteil, Paris, France
    Curr Drug Targets 12:1082-93. 2011
    ..The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy...
  86. ncbi Cyclooxygenase regulates angiogenesis induced by colon cancer cells
    M Tsujii
    Department of Medicine, Vanderbilt University Medical Center, VA Medical Center, Nashville, Tennessee 37232, USA
    Cell 93:705-16. 1998
    ..Cyclooxygenase regulates colon carcinoma-induced angiogenesis by two mechanisms: COX-2 can modulate production of angiogenic factors by colon cancer cells, while COX-1 regulates angiogenesis in endothelial cells...
  87. ncbi Pathogenesis of aspirin-exacerbated respiratory disease
    Donald D Stevenson
    Allergy and Immunology Division, Scripps Clinic and the Scripps Research Institute, La Jolla, CA 92037, USA
    Clin Rev Allergy Immunol 24:169-88. 2003
    ..It is more likely that a diminution in number or function of cysLT receptors accounts for the diminished inflammatory response found in ASA desensitization...
  88. ncbi Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis
    Caname Iwata
    Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Cancer Res 67:10181-9. 2007
    ..Our findings suggest that COX-2 inhibitor may be useful for prophylaxis of lymph node metastasis by reducing macrophage-mediated tumor lymphangiogenesis...
  89. ncbi Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
    Sulma I Mohammed
    Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana 47907, USA
    Cancer Res 62:356-8. 2002
    The mechanisms by which cyclooxygenase inhibitors exert antitumor effects are not completely defined but are postulated to involve antiangiogenic effects and induction of apoptosis...
  90. ncbi COX-2: a target for colon cancer prevention
    Lawrence J Marnett
    A B Hancock Jr Memorial Laboratory for Cancer Research, Center in Molecular Toxicology, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Annu Rev Pharmacol Toxicol 42:55-80. 2002
    ..It is hoped that, as the genome sequence is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention...
  91. ncbi Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma
    Christoph Bergmann
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    Cancer Res 67:8865-73. 2007
    ..Neutralizing mAbs to IL-10 and/or TGF-beta(1) abolished Tr1-mediated suppression. COX-2 overexpression in HNSCC plays a major role in the induction of Tr1 cells in the tumor microenvironment...
  92. ncbi Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice
    Padi S V Satyanarayana
    Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India
    Prog Neuropsychopharmacol Biol Psychiatry 28:641-9. 2004
    ..The results demonstrated marked synergistic interaction between naproxen and tramadol and such interaction involved opioid as well as non-opioid mechanisms of tramadol and inhibition of COX-1 but not COX-2 by naproxen...
  93. ncbi Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer
    N Kundu
    Program in Oncology, University of Maryland Greenebaum Cancer Center and School of Medicine, Baltimore, MD 21201, USA
    Int J Cancer 93:681-6. 2001
    ..Despite the inhibition of prostaglandin synthesis, the cox-2 enzyme levels (protein and mRNA) were increased by either indomethacin or NS398...
  94. ncbi Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors
    Sabine Grosch
    Pharmazentrum Frankfurt, ZAFES, Institut fur Klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe, Universitat Frankfurt, Theodor Stern Kai 7, Frankfurt Main, Germany
    J Natl Cancer Inst 98:736-47. 2006
    ..We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs...
  95. ncbi Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy
    Corrado Blandizzi
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma 55, Pisa 56126, Italy
    Pharmacol Res 59:90-100. 2009
    ....
  96. ncbi Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, United Kingdom
    J Clin Oncol 28:4575-80. 2010
    ..The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer (CRC)...
  97. ncbi The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
    N Muller
    Hospital for Psychiatry and Psychotherapy, Ludwig Maximilians Universitat, Munchen, Germany
    Mol Psychiatry 11:680-4. 2006
    ..Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated...
  98. ncbi Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay
    U Huss
    Division of Pharmacognosy, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, SE 751 23 Uppsala, Sweden
    J Nat Prod 65:1517-21. 2002
    ..This study showed that a COX-2-catalyzed PGE(2) assay using SPA is suitable for screening natural compounds with respect to COX-2 inhibition...
  99. pmc Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:2104-13. 2008
    ..Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events...
  100. ncbi Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer
    Jingsong Chu
    Signal Transduction Laboratory, Methodist Research Institute, Indianapolis, Indiana 46202, USA
    Mol Cancer Ther 2:1-7. 2003
    ....
  101. ncbi Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis
    Jing Leng
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Hepatology 38:756-68. 2003
    ..01). In conclusion, our results suggest the involvement of COX-2-dependent and -independent mechanisms in celecoxib-mediated HCC cell apoptosis...

Research Grants63

  1. New Pathways in Thrombosis and Inflammation Mediated by Semaphorin-Plexin Signali
    Guy A Zimmerman; Fiscal Year: 2010
    ..could potentially be used independently or in combination with other antithrombotic therapies including cyclooxygenase inhibitors (aspirin), thienopyridines (clopidogrel), and anticoagulants (heparin, warfarin)...
  2. Mechanism of HPA Axis Activation: Role of Nicotinic Acid Receptor in the Brain
    Jang H Youn; Fiscal Year: 2012
    ..g., diabetes and anorexia nervosa) and unwanted effects of the nicotinic acid therapy for lipid control. ..
  3. Renal Processing of Albumin
    Oliver Smithies; Fiscal Year: 2010
    ..Our preliminary data show that in normal mice angiotensin converting enzyme and/or cyclooxygenase inhibitors in high dose cause temporary reversible albuminuria, exacerbated by a low salt diet...
  4. Eicosanoid regulation of experimental Lyme arthritis
    Charles R Brown; Fiscal Year: 2010
    ..This information will further our understanding of how inflammation is regulated and allow the design of more effective anti-inflammatory treatments. ..
  5. The Role of Bioactive Lipids in Inflammation and Cancer
    RAYMOND NELSON DUBOIS; Fiscal Year: 2013
    ..Information gained from these studies will be important for achieving the long-term goal of reducing the cancer burden and revealing more effective ways to prevent cancer. ..
  6. Metabolism, protein and miRNA cross-talk in cell cycle and tumor progression
    David M Hockenbery; Fiscal Year: 2013
    ..We also demonstrated increased prostaglandin E2 in media, and that cyclooxygenase inhibitors had selective anti-proliferative effects for Myc-expressing cells...
  7. PG-INDUCED REDUCTION OF INTRAOCULAR PRESSURE
    Carl Camras; Fiscal Year: 1993
    ..Argon laser treatment to the peripheral iris and Nd:YAG laser treatment to the trabecular mesh-work will be performed in cats to determine whether they also result in reduction of IOP mediated by PGs...
  8. Catalysis by Prostaglandin Endoperoxide H Synthases
    William L Smith; Fiscal Year: 2013
    ....
  9. PROSTAGLANDINS AND LOCAL CONTROL OF THE CIRCULATION
    ALAN NIES; Fiscal Year: 1990
    ..hydralazine and thiazides enhance vascular prostacyclin synthesis, which accounts for the ability of cyclooxygenase inhibitors to reduce the antihypertensive efficacy and 2) clinical studies on furosemide induced venodilation and ..
  10. SEROTONIN AND EICOSANOID INTERACTION IN LUNG VASOMOTION
    WENDELL HOFMAN; Fiscal Year: 1992
    ..segmental distribution of PVR attendant to varying degrees of COI induced by three chemically dissimilar cyclooxygenase inhibitors (aspirin, meclofenamate and indomethacin)...
  11. CELLULAR MECHANISMS OF CHOLECYSTITIS AND COLITIS
    DONALD KAMINSKI; Fiscal Year: 1999
    ..Previous studies have demonstrated that cyclooxygenase inhibitors are specific drugs for the treatment of gallbladder disease...
  12. ALCOHOLIC EMBRYOPATHY & MATERNAL HYPERTENSION
    RUSSELL MANKES; Fiscal Year: 1992
    ..agents and to prostaglandin and thromboxane agonists; and to prostaglandin receptor blocking drugs and cyclooxygenase inhibitors. 5...
  13. Eicosanoids and Diabetic Retinopathy
    Rose Gubitosi Klug; Fiscal Year: 2009
    ..The candidate's preliminary data suggest that both lipoxygenase and cyclooxygenase inhibitors can ameliorate the high glucose-induced cell death seen in cultured retinal endothelial cells...
  14. Use of Novel Cox-2 Inhibitors in Neurological Disorders
    STANLEY BELL; Fiscal Year: 2006
    ....
  15. PROSTANOID BIOSYNTHESIS IN SYSTEMIC MASTOCYTOSIS
    John Oates; Fiscal Year: 2003
    ..Inhibition of PGD2 biosynthesis with nonselective cyclooxygenase inhibitors (the nonsteroidal anti- inflammatory drugs) has been employed in the treatment of this disorder, but ..
  16. EVALUATION OF THE NASAL LATE PHASE RESPONSE TO ANTIGEN
    Robert Naclerio; Fiscal Year: 1993
    ..is the evaluation of existing therapies, including antihistamines, topical and systemic corticosteroids, cyclooxygenase inhibitors and immunotherapy, to determine their effect on the response to nasal challenge...
  17. EVALUATION OF THE NASAL LATE PHASE RESPONSE TO ANTIGEN
    Robert Naclerio; Fiscal Year: 1990
    ..is the evaluation of existing therapies, including antihistamines, topical and systemic corticosteroids, cyclooxygenase inhibitors and immunotherapy, to determine their effect on the response to nasal challenge...
  18. IMAGING COX-2 GENE EXPRESSION IN INFLAMMATION AND TUMORS
    Harvey Herschman; Fiscal Year: 2009
    ..Studies with this mouse will correlate optical and microPET imaging technologies. ..
  19. Novel Cyclooxygenase-2 Inhibitors: Epileptogenesis
    STANLEY BELL; Fiscal Year: 2005
    ..The later studies for Phase 2 and Phase 3 evaluations can be earned out internally or with a commercial partner, depending on the results of the early studies and the needs of the company. ..
  20. Flow cytometry for novel regulators of inflammation
    ELLEN BERG; Fiscal Year: 2001
    ..Many anti-inflammatory drugs, including corticosteroids, cyclooxygenase inhibitors and lipoxygenase inhibitors, inhibit the cytokine-dependent expression of certain endothelial cell ..
  21. COX2 EXPRESSION IN GENITOURINARY CANCER AND DEVELOPMENT
    Matthew Breyer; Fiscal Year: 2001
    ..second, mitogen inducible isoform, occurred almost simultaneously with realization that patients taking cyclooxygenase inhibitors including aspirin and other non-steroid anti-inflammatory drug (NSAIDs) had nearly a 40% risk reduction ..
  22. Oxidative Modifications in Atherogenesis
    Garret FitzGerald; Fiscal Year: 2006
    ..abstract_text> ..
  23. Novel Imaging to Predict Cardiovascular Events in Diabetes
    Zahi A Fayad; Fiscal Year: 2010
    ..It is our expectation that our data will be utilized to evaluate and improve existent treatment and develop effective new therapies to decrease the burden of atherosclerotic disease in diabetes. ..
  24. Osteoporosis in Women with Rheumatoid Arthritis
    Daniel Solomon; Fiscal Year: 2006
    ..This epidemiologic data will inform future trials of osteoporosis treatments among patients with RA. As well, the study cohort will comprise one of the largest RA registries with an explicit plan to examine osteoporosis. ..
  25. Periodontal Assessment in RA Study (PARAS)
    Clifton Bingham; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  26. Randomized Controlled Testing of Osteoporosis Education
    Daniel Solomon; Fiscal Year: 2006
    ..A multi-disciplinary Training Advisory Board will review the applicants progress regularly to ensure that the proposed training goals are met. ..
  27. Research Conference:Mutagenesis and Carcinogenesis
    LAWRENCE MARNETT; Fiscal Year: 2004
    ..Leading scientists in the field will present and evaluate the latest research at the frontiers of mutagenesis and carcinogenesis. ..
  28. Clinical Studies with Phospholipid-Associated NSAIDs
    Lenard Lichtenberger; Fiscal Year: 2004
    ..i.d.) with diclofenac-PC, except in this case we will add a third arm of the study in which the subjects are administered the COX- inhibitor, Celecoxib, at a dose (200 mg b.i.d.) having equivalent therapeutic efficacy to diclofenac. ..
  29. Why is Cardiac Risk Increased in Rheumatiod Arthritis
    Daniel Solomon; Fiscal Year: 2002
    ..ability to control for known cardiovascular risk factors, the extensive medication information allowing for us to explore key hypotheses regarding corticosteroid exposure, and the attempt to simultaneously control for disease severity ..
  30. CHEMISTRY AND BIOLOGY OF MALONDIALDEHYDE DNA ADDUCTS
    LAWRENCE MARNETT; Fiscal Year: 2004
    ..The results of these experiments will define the chemistry and biology of a family of structurally dynamic lesions in the genome derived from an endogenous metabolic product of lipid oxidation. ..
  31. Pain Medication Use & Risk Factors for Opioid Dependence
    Daniel Solomon; Fiscal Year: 2004
    ..Our goal is to use the results of the proposed research to inform a future intervention to improve opioid prescribing within this large pharmacy benefits program. ..
  32. PHOSPHOLIPIDS AND ULCER PROTECTION
    Lenard Lichtenberger; Fiscal Year: 2002
    ....
  33. Contraceptive efficacy and body weight: Does obesity affect the risk of failure?
    Alison Edelman; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  34. LUNG CANCER CHEMOPREVENTION WITH CELECOXIB IN EX-SMOKERS
    Jenny Mao; Fiscal Year: 2007
    ..The finding from this pilot project will provide important insight into the design and conduct of future chemopreventive trials. ..
  35. Vessel Remodeling During Ductus Arteriosus Closure
    Ronald I Clyman; Fiscal Year: 2010
    ..These studies should increase our understanding of the mechanisms that prevent the preterm DA from closing and remodeling after birth. ..
  36. Analgesics and resistance training in older individuals
    Todd Trappe; Fiscal Year: 2008
    ..This investigation will provide important information for clinicians and older individuals with regard to expected benefits from physical activity during periods of analgesic and anti-inflammatory based therapy. ..
  37. ADAPTATION OF SENESCENT MUSCLE TO EXERCISE TRAINING
    Todd Trappe; Fiscal Year: 2002
    ....
  38. Immune Reactants, Cholesterol and Atherosclerosis
    ALLISON REISS; Fiscal Year: 2006
    ..abstract_text> ..
  39. PREVENTION OF COLORECTAL CANCER BY iNOS AND COX-2 SELECTIVE INHIBITORS
    CHINTHALAPALLY RAO; Fiscal Year: 2008
    ..abstract_text> ..
  40. MECHANISMS FOR CHEMOPREVENTION OF COLON CANCER
    CHINTHALAPALLY RAO; Fiscal Year: 2004
    ..Tissue distribution and comparative metabolism studies of curcumin and PEMC will be studied with synthetic [3H] curcumin and [3H]-PEMC in vivo in male F-344 rats. ..
  41. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  42. Improving Contraceptive Effectiveness in Obese Women
    Alison B Edelman; Fiscal Year: 2010
    ..abstract_text> ..
  43. THE BIOLOGY OF PROGRESSIVE NEPHRON DESTRUCTION
    Raymond Harris; Fiscal Year: 2007
    ..abstract_text> ..
  44. ESTROGEN BIOTRANSFORMATIONS AND BREAST CANCER ETIOLOGY
    ROBERT BRUEGGEMEIER; Fiscal Year: 2006
    ..3) To measure cellular levels of aromatase expression and cyclooxygenases expression in human breast cancer specimens. ..
  45. Sympathetic Nerve Activity and the Skeletal Myopathy of Heart Failure
    Holly R Middlekauff; Fiscal Year: 2010
    ..2.1 Is the sympatholysis with clonidine associated with a reversal of the skeletal myopathy in HF? 2.2 What is the effect of the improved skeletal myopathy on muscle mechanoreceptor sensitivity in HF? ..
  46. CANCER AND LEUKEMIA GROUP B
    Martin Edelman; Fiscal Year: 2002
    ..The grant will also allow for continuation of meritorious pilot protocols and will allow GCC to monitor and collect data which will produce mutual benefit to the GCC and CALGB. ..
  47. Air Pollution and Central Nervous System Disease
    Lilian Calderon Garciduenas; Fiscal Year: 2008
    ..The Award will give me the opportunity to build new skills in 4 areas: Molecular Biology, DNA Damage, Developmental / Neurodegenerative Neuropathology, and to gain experience in grantsmanship. [unreadable] [unreadable]..
  48. Drug-Induced sudden death & ventricular arrhythmia
    Sean Hennessy; Fiscal Year: 2008
    ..Finally, this project will create a valuable and lasting pharmacoepidemiologic data resource that can be brought to bear in future drug safety studies. [unreadable] [unreadable]..
  49. LIPID PEROXIDATION AND APOE IN ALZHEIMERS DISEASE
    Thomas Montine; Fiscal Year: 2003
    ..This new information will aid in laying the foundation for designing rational therapeutic approaches to ameliorate brain oxidative damage in Alzheimer's disease. ..
  50. Toll-Like Receptors in Bacterial Antigen Induced HIV-LTR
    Ozlem Equils; Fiscal Year: 2004
    ..abstract_text> ..
  51. Muscle Pump and Chemical Dilation in Exercise Hyperemia
    William Schrage; Fiscal Year: 2004
    ..The strength of the proposed experiments is that we will manipulate both mechanical and chemical factors and assess their combined effects on muscle blood flow during acute and steady state exercise in humans. ..
  52. Diet and Risk of Ovarian Cancer
    Ellen Chang; Fiscal Year: 2005
    ..The results of the proposed analyses will provide further understanding of the etiology of ovarian cancer. ..
  53. THE MUTAGENICITY OF MINERAL FIBERS
    TOM HEI; Fiscal Year: 2006
    ..By using specific DNA probes of other genes that have been regionally mapped to various sites on chromosome 11, the molecular spectrum of mutations induced by either asbestos or glass fiber control will be compared. ..
  54. Role of iNOS and CAT-2 in defense against CP infection
    Jody Gookin; Fiscal Year: 2006
    ..parvum infection. The PI is presently in the 3rd year of a 5-year K08 from NIDDK. These studies are anticipated to generate key preliminary data for the PI's first R01 application ..
  55. Mechanistic Effects of Organic Selenium Against Colon C
    Mark Nelson; Fiscal Year: 2006
    ..abstract_text> ..
  56. The Perception of Cancer Risk in Patients with Barrett's Esophagus
    Nicholas Shaheen; Fiscal Year: 2007
    ..The resultant study application will assess health-related quality of life, health-related anxiety and healthcare utilization as outcomes. [unreadable] [unreadable]..
  57. Muscle Mechanosensitivity in Heart Failure
    Holly Middlekauff; Fiscal Year: 2004
    ..After a 4 week conditioning program, which reverses the myopathy of HF, the above testing repeated to determine if the muscle mechanoreceptor sensitization is reversible. ..
  58. Oxidative stress, Homocysteine and Alzheimer's Disease
    Domenico Pratico; Fiscal Year: 2008
    ..These studies will be a necessary basis before prevention studies aimed to reduce Hcy levels are initiated in patients at risk for AD. ..
  59. A novel sulindac derivative for colon cancer chemoprevention
    Gary Piazza; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  60. Prevention of Prostate Carcinogenesis in Transgenic Mice
    Susan Fischer; Fiscal Year: 2008
    ..IGF-1 model. ..
  61. Pulmonary Arterial Hypertension: Avian Model of Complex Vascular Lesion Developme
    ROBERT WIDEMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  62. RANDOMIZED TRIAL OF FOLATE AND COLORECTAL ADENOMA
    Edward Giovannucci; Fiscal Year: 2003
    ..abstract_text> ..